AbbVie Inc (ABBV)vsRetractable Technologies Inc (RVP)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
RVP
Retractable Technologies Inc
$0.69
+3.96%
HEALTHCARE · Cap: $20.95M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 169003% more annual revenue ($62.82B vs $37.15M). ABBV leads profitability with a 5.8% profit margin vs -16.9%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
RVP
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Intrinsic value data unavailable for RVP.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of -9.0% — below average capital efficiency
Revenue declined 13.5%
Earnings declined 66.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : RVP
The strongest argument for RVP centers on Price/Book, Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : RVP
The primary concerns for RVP are Market Cap, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
ABBV profiles as a value stock while RVP is a turnaround play — different risk/reward profiles.
RVP carries more volatility with a beta of 1.25 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 29/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Retractable Technologies Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other medical products for the healthcare industry in the United States, the rest of North and South America, and internationally. The company is headquartered in Little Elm, Texas.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?